ACT Genomics
Taipei
About ACT Genomics
ACT Genomics is a cancer molecular information service company teamed up with experts with multiple years’ experience in oncology, cancer genomics, and bioinformatics. The company’s technology provides the possibility to transform cancer genomic information into precision diagnosis and personalized treatments. Every patient’s cancer is unique at the molecular level. Specific genetic alterations drive the pathogenesis and determine the treatment response of individual tumor. Understanding the genetic alteration helps to design a more effective treatment strategy and provide a more accurate prediction for patient’s outcome. The use of genomics is changing the paradigm of oncology treatment decisions and making great impacts on personalized treatment. Such comprehensive tumor profiling is now affordable due to rapid progress in sequencing and informatics technologies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Estimated revenue: $1K – $10K
- Total funding: $20.5M
- Funding stage: M&A
- Last round: Series Unknown (Sep 2020)
- Website: actgenomics.com
- Phone: +886227953660
Industries & Categories
Bioinformatics, Biotechnology, Genetics, Health Care, Information Technology
Social Profiles
Canonical: https://fsome.com/organization/act-genomics-141380 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.